RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
    1.
    发明申请
    RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA 审中-公开
    肿瘤坏死因子α信号通路治疗玻璃体的RNAi相关抑制

    公开(公告)号:US20150057336A1

    公开(公告)日:2015-02-26

    申请号:US14484972

    申请日:2014-09-12

    IPC分类号: C12N15/113

    摘要: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (TOP), including glaucoma and ocular hypertension.

    摘要翻译: 通过沉默TNFα细胞表面受体TNF受体-1(TNFR1)mRNA表达或沉默TNFα转化酶(TACE / ADAM17)mRNA表达,提供RNA干扰抑制肿瘤坏死因子α(TNFα)。 特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症风险的患者,如与眼内压升高(TOP)相关的眼部疾病,包括青光眼和高眼压症。